Nabriva Therapeutics plc
nabriva.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Oct 19, 2023. Its latest SEC filing is a 15-12G from Oct 25, 2023.
10-Q for Q2 FY2023, filed Oct 19, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Sells antibiotic products for serious infections, including SIVEXTRO and XENLETA, to pharmaceutical wholesalers and distributors, and holds development candidate CONTEPO.
10-K for FY2022, filed Apr 17, 2023We are a biopharmaceutical company that historically engaged in the commercialization and research and development of novel anti-infective…View ↗
SIVEXTRO is a novel oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens including MRSA, one of the serious public…View ↗
Discovered and developed by our team, XENLETA is a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV…View ↗
On July 24, 2018, we completed the acquisition of Zavante Therapeutics, Inc., or Zavante, together with its lead product candidate CONTEPO…View ↗
The Company sells its products to pharmaceutical wholesalers/distributors (i.e., the Company’s customers). The Company’s…View ↗
How Did They Make Money?
Nabriva sells antibiotics to wholesalers and distributors, who generally pay about 60 days after invoicing; product sales are counted when the goods are delivered. It also receives collaboration revenue tied to a China-region license and support, plus government research premiums and grants tied to research spending and grant conditions.
10-K for FY2022, filed Apr 17, 2023In September 2019, the Company launched XENLETA and in April 2021 the Company began exclusive distribution of SIVEXTRO in the United States…View ↗
The Company sells its products to pharmaceutical wholesalers/distributors (i.e., the Company’s customers). The Company’s…View ↗
Collaboration revenues for the year ended December 31, 2022 were $0.9 million related to the restructured China Region License Agreement…View ↗
Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Austrian Research Promotion…View ↗
The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and…View ↗
-
10-K for FY2022, filed Apr 17, 2023
FY2022 revenue by product or service ↗
$36.9M
-
10-K for FY2022, filed Apr 17, 2023
$36.9M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2022, filed Apr 17, 2023 |
94%
FY2019: 16%
|
Product revenue, net, FY2022
$34.7M Sources
|
Sold outright |
|
Collaboration revenue
Licensed
|
2.5%
FY2019: 66%
|
Collaboration revenue, FY2022
$926K Sources
|
Licensed |
|
Research premium and grant revenue
|
3.4%
FY2019: 18%
|
Research premium and grant revenue, FY2022
$1.3M Sources
|
Who Were Their Customers?
Nabriva sells products directly to a limited number of specialty distributors and wholesalers, who resell them to clinics, hospitals and private practices.
10-K for FY2022, filed Apr 17, 2023
Did Revenues Turn Into Profits?
No. It lost $57.2M in FY2022.
10-K for FY2022, filed Apr 17, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2023, filed Oct 18, 2023
−$12.1MView ↗
- ▲ +9% (Loss)
- vs −$11.1M in Q2 FY2022
10-Q for Q2 FY2023, filed Oct 19, 2023
Open tableView ↗
-
Jul 31, 2023
Sold lefamulin assets in China, Hong Kong, Macau and Taiwan
Sumitomo Pharma paid $15.0 million upfront and assumed certain related liabilities.
Sources
8-K, filed Jul 31, 2023
Under the terms of the Asset Purchase Agreement, the Purchaser agreed to pay to the Company an upfront cash payment of $15.0 million upon…View ↗
-
Jul 24, 2023
Nasdaq issued a delisting determination; Nabriva said it would not appeal
Trading was set to be suspended unless the company appealed; Nabriva said it would not appeal.
Sources
8-K, filed Jul 24, 2023
On July 21, 2023, Nabriva Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The…View ↗
-
Jul 7, 2023
The CEO and CFO left during the wind-down
Their employment ended June 30 and July 7, respectively.
Sources
8-K, filed Jul 7, 2023
As previously disclosed, on January 4, 2023, the Board of Directors (the “Board of Directors”) of Nabriva Therapeutics plc (the “Company”)…View ↗
Grew. Revenue grew 3.8x in 4 years, from $9.7M in FY2018 to $36.9M in FY2022, about 40% a year.
From active development to wind-down
The older report describes active commercialization and ongoing development plans for XENLETA and CONTEPO. The latest report says the company has stopped active promotion and research and development and is focused on an orderly wind-down, while keeping products available to wholesalers.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Apr 17, 2023
Added SIVEXTRO distribution
The older report describes XENLETA and CONTEPO; the latest report also describes Nabriva as the U.S. distributor of SIVEXTRO.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Apr 17, 2023We are a biopharmaceutical company engaged in the research, development and commercialization of novel anti‑infective agents to treat…View ↗
Who Did They Compete With?
Competes with Paratek Pharmaceuticals, Melinta Therapeutics, Wockhardt, Merck &, Shionogi, Venatorx Pharmaceuticals, Allecra Therapeutics, Entasis Therapeutics, Spero, Iterum Therapeutics, and Novartis
10-K for FY2022, filed Apr 17, 2023There are a variety of available therapies marketed for the treatment of ABSSSI and CABP. Currently, the treatment of CABP is dominated by…View ↗
Loading...
